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p70 S6 kinase 1 (S6K) is a major downstream effector
of the mammalian target of rapamycin (mTOR), pri-
marily implicated in the control of protein synthesis,
cell growth, and proliferation. Here we demonstrate
that specific bidirectional molecular targeting of
mediobasal hypothalamic (MBH) S6K activity in rats
is sufficient to significantly alter food intake, body
weight, hypothalamic orexigenic neuropeptide ex-
pression, hypothalamic leptin sensitivity, and the
metabolic and feeding responses to a fast. In addi-
tion, adenoviral-mediated constitutive activation of
MBH S6K improved cold tolerance and protected
against high-fat diet-induced overeating, fat deposi-
tion, and insulin resistance. Our results provide direct
evidence that MBH S6K activity bidirectionally drives
behavioral and metabolic determinants of energy
balance and promote the assessment of MBH S6K
activity as a therapeutic target in metabolic diseases.
INTRODUCTION
In mammals, the mediobasal hypothalamus (MBH) is a primary
center of convergence and integration of nutrient-related signals
critical to the regulation of energy homeostasis (Schwartz et al.,
2000). In response to nutrients such as glucose and amino acids
and the adiposity hormones insulin and leptin, the MBH engages
both intracellular and extracellular signaling processes to coordi-
nately drive behavioral and metabolic determinants of energy
balance (Obici et al., 2002; Pocai et al., 2005b). Detailed knowl-
edge of hypothalamic nutrient-sensing pathways coupling
hormonal signaling and nutrient detection in the control of food
intake and energy homeostasis is essential to a better under-
standing of the mechanisms involved in the etiology of obesity
and associated diseases such as type 2 diabetes.
S6K is a major effector of the ubiquitous evolutionarily con-
served and multitasking mTOR, known to integrate nutrient
and insulin signals and control the initiation of protein synthesis,
cell growth, and proliferation in peripheral cells (Dennis et al.,
2001; Fingar et al., 2002). S6K is also widely expressed in the
central nervous system (Asaki et al., 2003), and recent data
suggest a role for neuronal mTOR/S6K pathways in the regula-
tion of energy balance, both in the fruit fly Drosophila mela-
nogaster (Wu et al., 2005) and in rats (Cota et al., 2006; Um
et al., 2004). In the hypothalamus, S6K is expressed in orexigenicCellneuropeptide Y (NPY) and agouti-related protein (AgRP) neu-
rons, as well as anorexigenic proopiomelanocortin (POMC) neu-
rons, two subpopulations of neurons involved in the regulation of
energy homeostasis (Cota et al., 2006). Hypothalamic S6K re-
sponds to intracerebroventricular hormonal and nutrient stimuli,
and central blockade of mTOR signaling blunts the anorexigenic
effects of these signals (Cota et al., 2006). These data leave un-
resolved the role of central S6K in driving multiple essential de-
terminants of overall energy balance and the specific neuroana-
tomical loci critical for this control.
Here we show that MBH S6K plays a critical role in the regula-
tion of food intake and energy balance in rats. Using adenovi-
ruses expressing a constitutively active and a dominant-negative
mutant of S6K, we demonstrate that specific bidirectional alter-
ation in MBH S6K activity is sufficient to significantly alter body
weight, primarily by changing food intake through altered MBH
NPY and AgRP expression. We also find that bidirectional alter-
ation in MBH S6K activity induces dramatic changes in leptin
sensitivity and alters the metabolic and feeding response to
a fast, indicating that signaling through MBH S6K is required
for an appropriate response to multiple indices of energy
availability. Adenoviral-mediated constitutive activation of S6K
also induced changes in energy expenditure, together with an
improved ability to maintain body core temperature during
a cold challenge. Finally, MBH S6K overactivation protects
against high-fat diet-induced overeating, fat deposition, and
insulin resistance. Our results provide direct evidence that
MBHS6K activity bidirectionally drives behavioral andmetabolic
determinants of energy balance, and promote its assessment as
a therapeutic target in metabolic diseases.
RESULTS
MBH S6K Activity Responds to Physiological Nutritional
and Hormonal Signals
To begin to assess the physiological relevance of MBH S6K as
an energy sensor, we first evaluated the degree to which food in-
take modulates MBH S6K activity in rats. The expression of the
active form of S6K, phosphorylated at Thr389, was significantly
increased within 3 hr of feeding following a 24 hr fast (Figure 1A).
We then examined whether local hypothalamic administration of
the adiposity hormone leptin would alter MBHS6K activity. Bilat-
eral intra-MBH leptin administration (150 ng in 150 nl per side)
induced a 4-fold increase in MBH Thr389 phosphorylation within
30 min of leptin injection (Figure 1B). Together, these data indi-
cate that MBH S6K rapidly responds to nutritional and hormonal
signals important for the feedback control of energy intake.Metabolism 8, 459–467, December 3, 2008 ª2008 Elsevier Inc. 459
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and Body Weight
We investigated the specific role of MBH S6K in the regulation of
energy balance by targeting the arcuate nucleus of the hypothal-
amus with recombinant adenovirus expressing a constitutively
active mutant of S6K (CA S6K), a dominant-negative mutant of
S6K (DN S6K), or lacZ (control), and evaluated the impact of
these viral manipulations on several behavioral andmetabolic ef-
fectors of energy balance. MBH CA S6K and DN S6K injections
induced a 5- to 40-fold increase in S6K protein expression in the
MBH compared to endogenous levels, without altering S6K pro-
tein expression in the paraventricular (PVN) or lateral hypotha-
lamic nuclei (Figure S1). Recombinant adenovirus functional val-
idity was confirmed in GT1-7 hypothalamic cell lines (Figures
S2A and S2B) as well as in MBH extracts from injected animals.
MBH expression of CA S6K and DN S6Kmutants induced signif-
icant changes in S6K’s target ribosomal S6 protein activity, as
assessed by its phosphorylation at Ser235/236 (Figure S2C),
and CA S6K increased MBH S6K activity by 4.5-fold relative to
lacZ controls (Figure S2D).
During the first 3 days following adenovirus injections, rats ex-
pressing DN S6K were protected against the acute weight loss
and the decrease in food intake typically induced by brain paren-
chymal injections and observed in rats expressing either lacZ or
CA S6K (Figures 2A and 2B). Conversely, MBH expression of CA
S6K significantly decreased food intake beginning on the third
day following the adenovirus injections, leading to a slower
rate of weight gain when compared to the lacZ controls. These
changes in food intake in both DNS6K andCAS6Kwere attribut-
able to changes in the average meal size (Figure S3A), whereas
daily meal number did not significantly differ among groups at
any time point (Figure S3B). Cumulative food intake over 9
days was also decreased in rats expressing CA S6K compared
to lacZ controls (p = 0.004), and this was associated with de-
creases in MBH expression of orexigenic neuropeptides NPY
and AgRP in CA S6K rats compared to lacZ pair-fed controls
(Figures 2C and 2D), whereas MBH POMC expression did not
significantly differ between these groups (Figure 2E). In DN
S6K rats, MBH feeding neuropeptide expression did not
significantly differ from lacZ controls. Body composition did
Figure 1. Refeeding and Leptin Induce MBH S6K Phosphorylation
(A and B) MBH S6K Thr389 phosphorylation (A) in 24-hr-fasted (n = 5) or 24-hr-
fasted and 3-hr-refed (n = 5) rats and (B) in rats 30min after bilateral MBHaCSF
(n = 4) or MBH leptin (n = 4) injection (150 ng in 150 nl). All data are means
±SEM.
Figure 2. Bidirectional Molecular Targeting of MBH S6K Activity Is Sufficient to Alter Food Intake and Body Weight
(A and B) Changes in body weight (A) and changes in food intake (B) after MBH injection of CA S6K (n = 12, filled triangle), DN S6K (n = 13, filled square), or lacZ
(n = 18, open circle).
(C–E) MBH NPY mRNA (C), MBH AgRP mRNA (D), and MBH POMC mRNA (E) levels are normalized to that of actin in CA S6K, DN S6K, lacZ, and lacZ pair-fed
controls (n = 6–8). Cumulative food intake over 9 days is 231.7 ± 9.4, 275.27 ± 6.65, and 269.1 ± 7.4 in CA S6K, DN S6K, and lacZ controls, respectively. All data
are means ±SEM.460 Cell Metabolism 8, 459–467, December 3, 2008 ª2008 Elsevier Inc.
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(A–D) Food intake (A), oxygen consumption (B), respiratory quotient (C), and physical activity (D) before (average of day 1 to day 3) and after (average of day 5
to day 7) MBH adenoviral injection in CA S6K (filled bar, n = 4) or lacZ pair-fed controls (open bar, n = 4).
(E) Change in body weight in CA S6K (n = 12, filled triangle) and lacZ pair-fed (open square, n = 9) mice. All data are means ±SEM.not differ between groups (data not shown). Thus, bidirectional
modulation of MBH S6K activity is sufficient to produce comple-
mentary bidirectional changes in food intake and body weight.
MBH S6K Activity Bidirectionally Affects Energy
Expenditure and Cold Tolerance
We next examined whether the decrease in food intake mea-
sured in CA S6K rats was associated with chronic changes in en-
ergy metabolism that could contribute to their reduced rate of
body weight gain. CA S6K injection induced a specific decrease
in nighttime food intake (Figure 3A), accompanied by decreased
nighttime oxygen consumption and metabolic rate (Figures 3B
and 3C). In contrast, no changes in oxygen consumption and
metabolic rate were observed in lacZ pair-fed controls. CACell MS6K rats did not differ from lacZ pair-fed controls in the day/night
distribution or amount of locomotor activity (Figure 3D). These
results, together with the absence of a difference in postinjection
body weight gain in CA S6K rats compared to lacZ pair-fed con-
trols (Figure 3E), support the interpretation that increased MBH
S6K activity reduced body weight gain primarily by reducing
ad libitum food intake.
We further tested the effect of MBH S6K overactivation on
energymetabolism in the context of ametabolic challenge by as-
sessing the ability of MBHCAS6K, lacZ, and lacZ pair-fed rats to
maintain body core temperature during cold exposure. CA S6K
rats maintained their core temperature at significantly higher
levels during the challenge compared to lacZ and lacZ pair-fed
controls (Figure 4A). Consistent with this difference, mRNA levelsetabolism 8, 459–467, December 3, 2008 ª2008 Elsevier Inc. 461
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(UCP1) in intrascapular brown adipose tissue were increased in
CA S6K rats relative to lacZ and lacZ pair-fed controls (Figures
4B and 4C). In contrast, cold tolerance in DN S6K-expressing
rats tended to be lower than in lacZ controls (Figure S4A).
Body core temperature after 5 hr at 16C was lower in DN
S6K rats (p = 0.05) (Figure S4B), and accordingly, brown adipose
tissue UCP1 protein level was lower in DN S6K rats than in lacZ
controls (Figure S4D), with no change in brown adipose tissue
UCP1 mRNA level (Figure S4C). Thus, bidirectional modulation
of MBH S6K activity is sufficient to produce complementary bi-
directional changes in adaptive thermogenesis and sympathetic
drive to intrascapular brown fat during a cold challenge.
MBH S6K Affects the Energetic Response
to a Fast and MBH Leptin Sensitivity
To extend our analysis of the relationship betweenMBH S6K ac-
tivity and nutrient availability, we assessed whether bidirectional
alteration of MBH S6K activity would affect the feeding and met-
abolic responses to a 24 hr fast. Rats expressing CA S6K were
partially protected against the 24 hr fasting-induced body weight
loss that was observed in lacZ pair-fed controls, whereas DN
S6K rats tended to lose more body weight than ad libitum-fed
lacZ controls (p = 0.08) (Figure 5A). Moreover, 3 hr food intake
following the 24 hr fast was significantly lower in CA S6K rats
than in lacZ pair-fed controls and, conversely, significantly
higher in DN S6K rats than in ad libitum-fed lacZ controls
(Figure 5B).
Because MBH S6K affected adaptive energy intake and met-
abolic responses to reduced nutrient availability during a fast, we
next investigated whether MBH S6K activity mediates feeding
and metabolic responses to MBH administration of the adiposity
hormone leptin. In rats expressing CA S6K, leptin-induced
reductions in body weight and food intake were significantly
more pronounced than in lacZ controls, whereas in rats express-
ing DN S6K, MBH leptin had no effect on either measure (Figures
Figure 4. Constitutive Activation of MBH S6K Increases Thermogenesis During a Cold Challenge
(A–C) Core temperature during a 5 hr cold challenge at 16C 7 days after adenoviral injection in CA S6K (filled triangle, n = 6), lacZ (open circle, n = 4), or lacZ
pair-fed controls (open square, n = 4) (A). Intrascapular brown adipose tissue UCP1 mRNA level is normalized to actin (B) and protein level is normalized to actin
(C) in lacZ (n = 7), lacZ pair-fed (n = 7), and CA S6K rats (n = 9). All data are means ±SEM.
Figure 5. Bidirectional Alteration of MBH S6K Activity Modulates the Metabolic and Feeding Response to a 24 hr Fast
(A) Changes in body weight after a 24 hr fast in lacZ (n = 10), lacZ pair-fed (n = 10), CA S6K (n = 10) and DN S6K (n = 10) rats.
(B) Three hour food intake following a 24 hr fast in lacZ (n = 5), lacZ pair-fed (n = 5), CA S6K (n = 5), and DN S6K (n = 5) rats. All data are means ±SEM.462 Cell Metabolism 8, 459–467, December 3, 2008 ª2008 Elsevier Inc.
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sensitivity could not be explained by alterations in leptin-induced
STAT3 activation, because MBH leptin induced a similar in-
crease in STAT3 Tyr705 phosphorylation in all groups (Figure S5),
indicating that S6K functions downstream of or in a parallel path-
way to STAT3. These data demonstrate that MBHS6K activation
is required for MBH leptin’s effects on energy balance.
MBH S6K Constitutive Activation Protects against
High-Fat Diet-Induced Disorders
Finally, we examined the effects of MBH S6K activation under
conditions that stimulate feeding during exposure to a palatable
high-fat diet (HFD). Unlike lacZ controls, CA S6K rats failed to ex-
hibit any sustained overeating beginning 2 days after a shift to
HFD (Figure 7A). Accordingly, body weight gain was significantly
lower in CA S6K rats than in lacZ controls (Figure 7B). In addition,
CA S6K rats were partially protected against the 2.3-fold
increase in fat mass observed in lacZ controls 10 days after
the shift (Figure 7C). In the context of a global assessment of
the onset of a metabolic syndrome after the shift to the HFD,
we also measured oral glucose tolerance in this cohort of
animals. During an oral glucose tolerance test, CA S6K rats
had lower plasma insulin levels than lacZ controls, suggesting
that MBH S6K overactivation protects against high-fat diet-in-
duced insulin resistance (Figures 7D and 7E). Taken together,
these data support the interpretation that hypothalamic S6K
Figure 6. Bidirectional Molecular Targeting
of MBH S6K Activity Is Sufficient to Alter
Hypothalamic Leptin Sensitivity
(A–B) Twenty-four hour change in body weight (A)
and 24 hr food intake (B) after MBH artificial
cerebrospinal fluid (open bar) versus leptin (150 ng
in 150 nl per side, filled bar) injections in lacZ
(n = 9), CA S6K (n = 6), and DN S6K rats (n = 5).
All data are means ±SEM.
Figure 7. Constitutive Activation of MBH S6K Protects against Adverse Effects of a HFD
(A and B) Energy intake (A) and changes in body weight (B) after MBH injection of CA S6K (n = 6, filled triangle) or lacZ (n = 6, open circle) and shift to a HFD.
(C) Fat mass (FM) in CA S6K (n = 6, filled bar) or lacZ (n = 6, open bar) rats before (day 3) and 10 days after (day 13) a shift to a HFD.
(D and E) Blood glucose (D) and plasma insulin (E) during an oral glucose tolerance test (1g/kg) in lacZ (open circles, n = 6) and CA S6K (filled squares, n = 6) rats
10 days after a shift to a HFD. All data are means ±SEM.Cell Metabolism 8, 459–467, December 3, 2008 ª2008 Elsevier Inc. 463
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tures of the metabolic syndrome in high-fat-fed rats.
DISCUSSION
Our data provide several converging lines of evidence under-
scoring the importance of endogenous MBH S6K in energy
homeostasis: (1) MBH S6K is activated by multiple physiological
signals of nutrient availability; (2) bidirectional alteration of MBH
S6K activity is sufficient to elicit complementary bidirectional
changes in body weight, food intake, and cold tolerance; and
(3) MBH S6K upregulation is consistently associated with an in-
creased sensitivity to anorexigenic stimuli (refeeding, leptin) and
a decreased sensitivity to orexigenic stimuli (fasting, HFD), while
the reciprocal pattern of responses occurs during MBH S6K
downregulation. Together, these findings demonstrate that
MBH S6K is a physiologically relevant nutrient sensor and a crit-
ical mediator required for appropriate feeding and metabolic
responses that maintain energy balance.
The rapid ability of DN S6K to promote food intake and body
weight gain in the days immediately following MBH injection
strongly argues in favor of a role for endogenous MBH S6K in
the regulation of energy balance. These effects disappear after
5 days, most likely due to the competitive nature of the downre-
gulation that could engage compensatory mechanisms to en-
sure the maintenance of energy homeostasis. In contrast, within
1 day of the injection recovery time, MBH CA S6K-induced an-
orexia and reduced body weight gain is sustained during normal
chow and high-fat diet maintenance, indicating that any effective
counterregulatory response to CA S6K expression is prevented.
These results may appear discordant with the phenotype of
S6K/ mice (Um et al., 2004), which are protected against
age- and diet-induced obesity, but this apparent difference
most likely reflects the direct effects of S6K deficiency on energy
expenditure in peripheral tissues (Kahn and Myers, 2006). These
apparently divergent responses of the periphery and the central
nervous system to suppression of S6K signaling reflect their
differential roles in maintaining adequate responses to nutrient
surfeit or nutrient deficit, as has been reported for other signals
(Caspi et al., 2007).
Whole body knockdown of S6K is also associated with in-
creased insulin sensitivity (Um et al., 2004), a finding consistent
with results reporting feedback inhibition exerted by S6K on in-
sulin signaling through activation of IRS1 serine phosphorylation
(Tremblay et al., 2007). Recent data indicate that prolonged
hypothalamic activation of S6K also leads to decreased insulin
signaling in the MBH (Ono et al., 2008). These data support the
prediction that in rats expressing CA S6K, decreased MBH an-
orexigenic insulin/PI 3 kinase signaling would induce hyperpha-
gia and increased weight gain (Niswender et al., 2003), in con-
trast to what we report in the current work. This contrast
suggests that MBH signaling pathways regulating glucose
homeostasis and food intake do not entirely overlap and in fact
diverge, at least at the level of S6K. Alternatively, activation of
S6K by the insulin/PI 3 kinase pathway may even contribute to
insulin’s anorexigenic effects, as suggested in the fruit fly
Drosophila (Wu et al., 2005).
The primary feeding phenotypes associated with bidirectional
alterations in MBH S6K activity represent novel central counter-464 Cell Metabolism 8, 459–467, December 3, 2008 ª2008 Elsevierparts to S6K’s well-known ability to trigger peripheral anabolic
processes (Fingar et al., 2002). Here we demonstrate that direct
MBH targeting of S6K alters feeding behavior, extending the role
of S6K as a nutrient sensor to include effects on whole body
energy availability. These changes in feeding behavior are man-
ifested by specific bidirectional consequences of MBH S6K
alteration on meal size, a critical index of satiety processes,
thereby positioning MBH S6K activation as part of the neural
basis of satiation (Azzara et al., 2002).
The present finding that bidirectional changes in MBH S6K ac-
tivity are associated with bidirectional changes in MBH leptin
sensitivity represent a direct and specific demonstration that
MBH S6K is a critical target of leptin in the regulation of energy
balance, as previously suggested (Cota et al., 2006). In agree-
ment with our results, recent findings indicate that the consump-
tion of a high-fat diet induces a decrease in hypothalamic S6K
signaling, both in the basal state and after an intracerebroven-
tricular leptin challenge (Cota et al., 2008), supporting the idea
that reduced hypothalamic S6K signaling contributes to the
development of leptin resistance in diet-induced obesity.
Downregulation of NPY and AgRP expression in rats express-
ing CA S6K suggests these two peptides and their PVN targets
as effectors of the feeding and metabolic responses to MBH
S6K activation. NPY deficiency is associated with a decreased
sensitivity to a fast and to a high-fat diet (Patel et al., 2006; Se-
gal-Lieberman et al., 2003), as we found in rats expressing CA
S6K. Impairment of MBH NPY release decreases food intake
(Burlet et al., 1995), whereas PVN NPY administration stimulates
feeding (Stanley and Leibowitz, 1985) and decreases sympa-
thetic outflow (van Dijk et al., 1994), and intracerebroventricular
NPY decreases brown adipose tissue thermogenesis (Billington
et al., 1991). These results are consistent with those observed
after alterations in MBH S6K activity. Moreover, MBH leptin ad-
ministration modulates this same cluster of markers, affecting
NPY synthesis (Nogueiras et al., 2008) and sympathetic outflow
(Rahmouni and Morgan, 2007) and altering food intake by spe-
cific effects on meal size (Moran et al., 2006; Morton et al.,
2005). Accordingly, several lines of evidence demonstrate that
reduced NPY release from theMBH to the PVNmediates leptin’s
hypophagic and thermogenic actions (Kotz et al., 1998; Wang
et al., 1997). Thus, similarly to leptin, the observed effects of al-
tered MBH S6K activity on food intake and thermogenesis could
be mediated by changes in MBH NPY release to the PVN.
Taken together, our findings establish a physiological role for
MBH S6K, an evolutionarily conserved nutrient-sensing enzyme,
in the regulation of energy balance in mammals. Hormonal and
nutritional signals inform the brain about whole body energy sta-
tus by altering the activity of a subset of neurons in the MBH that
in turn engage appropriate responses to regulate feeding and
energy expenditure (Schwartz et al., 2000). Our data demon-
strate that multiple indices of energy supply converge on MBH
S6K, and that signaling through MBH S6K is required for appro-
priate feeding and metabolic responses to variations in nutrient
availability. We propose that MBH S6K drives the regulation of
food intake and brown fat thermogenesis by regulating the
expression of AgRP and NPY. The present findings that MBH
S6K upregulation provides sustained protection against the de-
velopment of several markers of themetabolic syndromemake it
a compelling therapeutic target for intervention in the treatmentInc.
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be driven by understanding how the S6K pathway functions as
part of an integrated hypothalamic nutrient-sensing network.
EXPERIMENTAL PROCEDURES
Animals and Study Design
Experiments were performed on 10-week-old male Sprague-Dawley rats
(Charles River Laboratories) housed in individual cages and maintained in
a temperature-controlled room under a standard light/dark cycle with ad libi-
tum access to water and standard chow unless specifically indicated. Using
stereotaxic surgery performed under ketamine/xylazine anesthesia, rats
were bilaterally injected with adenovirus (2 3 106 pfu in 2 ml/side over
a 20 min period) expressing a constitutively active mutant of S6K (CA S6K),
a dominant-negative mutant of S6K (DN S6K), or lacZ in the MBH (coordinates
from bregma: A/P3.0 mm, D/V10.4 mm), and in some cases, a chronic bi-
lateral intrahypothalamic cannula (Plastics One, Inc.) was implanted. Body
weight, feeding behavior, energy expenditure, and physical activity were mon-
itored from 4 days before to 7–10 days after virus administration as described
below. Sensitivity to a fast was determined by measuring 24 hr fast-induced
body weight loss and 3 hr food intake during refeeding. In the high-fat diet shift
experiment, rats were shifted from a standard chow diet to a high-fat diet
3 days after MBH virus injection; shift-induced hyperphagia, weight gain, and
fat depositionweremonitored for 10days, andglucose tolerancewasassessed
with a 1g.kg1 BW oral glucose challenge. Body composition was determined
by magnetic resonance spectroscopy using an ECHO MRS instrument (Echo
Medical Systems). All rats were sacrificed by decapitation and hypothalamic
nuclei were dissected as previously described (Pocai et al., 2005a). Successful
adenovirus administration in the MBH was confirmed by immunoblot analysis
with S6K antibody. All experimental protocols were approved by the Institute
for Animal Studies of the Albert Einstein College of Medicine.
Feeding Studies
One week prior to adenovirus injection, rats (n = 70) were adapted to individual
feeding chambers (MedAssociates) equippedwith 45mgpellet dispensers and
fed ad libitum with a standard chow diet (Bio-Serv 45 mg precision pellets
F05524, 15.8 kJ/g) or a high-fat diet (TestDiet 45mgpellets 1812366, 18.4 kJ/g).
One group of rats treated with the lacZ virus (n = 9) was pair-fed to the CA S6K
group. Food intake was monitored continuously from 4 days before to 10–
14 days after virus administration, and body weight was assessed daily. Meal
patterns were determined as previously described (Azzara et al., 2002).
Indirect Calorimetry
One week prior to adenoviral injection, rats (n = 8) were adapted to individual
metabolic chambers. Metabolic measurements (oxygen consumption, carbon
dioxide production, food intake, and locomotor activity) were obtained contin-
uously using a CLAMS (Columbus Instruments) open-circuit indirect calorim-
etry system from 4 days before to 7 days after virus administration.
Cold Challenge
Prior to adenovirus injection, rats (n = 16)were implantedwith intraperitoneal ra-
diofrequency impedance temperature probes (MiniMitter) under isoflurane an-
esthesia and allowed a 1 week recovery. Seven days after virus administration,
rats were exposed to a 5 hr cold challenge at 16C, during which body core
temperature was recorded continuously using MiniMitter ER-4000 receivers.
MBH Leptin Sensitivity
One week after adenoviral injection, hypothalamic leptin sensitivity was as-
sessed by measuring 24 hr food intake and body weight change following a lo-
cal leptin injection in the MBH (recombinant rat leptin, R&D Systems, 150 ng in
150 nl per side). MBH leptin-induced STAT3 activation was assessed 7 days
after adenovirus injection in rats equipped with a bilateral cannula targeting
the MBH. Rats received an MBH injection of aCSF or leptin (150 ng in 150 nl
per side over 5 min), and MBH were collected 30 min later and processed
as described below.CellSubcloning and Adenovirus Preparation
Rat p70 S6 kinase 1 (shorter form of Rps6kb1) cDNAwas subcloned using RT-
PCR from rat liver. N-terminal FLAG tag and mutations in S6K at F5A, K100Q,
T389E, and RSPRR to ASPAA (AA410–414) were introduced using PCR-based
mutagenesis, with confirmation of whole sequences. Adenoviruses for S6K
mutants were generated using the Adeno-X Expression System 1 (BD Clon-
tech), with a substitution of the promoter in the shuttle vector from CMV to
CAG (Ono et al., 2003). LacZ adenovirus was prepared as previously de-
scribed (Ono et al., 2003). Adenovirus was amplified in 293 cells and purified
with an Adenopure kit (Puresyn, Inc.). Adenoviral titers were measured by end-
point dilution assay with 1:3 serial dilutions on a 96-well plate of HEK293 cells.
Adenovirus Functional Validation In Vitro
Hypothalamic GT1-7 cells (gift from Dr. Pamela Mellon) were infected with CA
S6K, DN S6K, or lacZ adenovirus. Forty-eight hours later, cells were serum
starved overnight and stimulated with 0, 1, 10, or 100 nM insulin for 30 min,
then harvested and processed as described below.
S6K Activity Assay
The p70 S6 kinase assay kit (Upstate) was used with minor modifications.
Briefly, 200 mg of tissue lysate was incubated with 3 mg of anti-S6K antibody
and 30 ml of Protein A Sepharose beads in modified buffer A (50 mM Tris
with pH of 7.5, 1 mM EDTA, 1 mM EGTA, 2 mM sodium orthovanadate,
0.1% 2-mercaptoethanol, 1% Triton X-100, 50 mM sodium fluoride, 10 mM
sodium pyrophosphate, 10mM b-glycerophosphate, 0.2mMPMSF, complete
inhibitor cocktail [Roche]) and agitated for 2 hr at 4C, then washed three times
with the same buffer and twice with Assay Dilution Buffer, then incubated with
synthetic substrate peptide (KKRNRTLTK) and g-32P-labeled ATP at 30C for
10 min with continuous agitation. After a brief spin down, supernatants were
spotted onto W81 filter paper, washed with diluted phosphoric acid, and
counted with a scintillation counter.
Real-Time PCR
Total RNAwas isolated from frozenMBHwedges (3–5 mg) and brown adipose
tissue (100 mg) using RNeasy Mini Kit (Quiagen) according to the manufac-
turer’s instructions. Extracted RNA was quantified using a NanoDrop 1000
(NanoDrop) and RNA integrity was confirmed with ethidium bromide staining.
Following treatment with DNase I (Invitrogen), purified RNA was used as tem-
plate for first-strand cDNA synthesis using SuperScript III (Invitrogen). Quanti-
tative real-time RT-PCRwas run using LC-Fast Start DNASYBRGreen I chem-
istry (Roche Diagnostics) on a LightCycler 2.0 platform (Roche Diagnostics).
Samples contained 2 ml Fast Start DNA Master SYBR Green I, 4mM MgCl2,
and 0.5 mM of each primer in a 20 ml final volume. Forward and reverse primer
pairs were as listed (Table S1). Samples of RNA in which the reverse transcrip-
tase was omitted and samples without cDNA were included as negative con-
trols. For each sample, the crossing point (CP) was determined at a constant
fluorescence threshold; for each target gene, PCR efficiency (E) was calcu-
lated using a series of 10-fold dilutions of cDNA. Relative quantification of








Signaling Studies and Western Blot Analysis
MBH wedges, brown adipose tissue and GT1-7 cells were homogenized in
50 mM Tris, 1 mM EGTA, 1 mM EDTA, 50 mM sodium fluoride, 10 mM
b-glycerophosphate, 20 mM sodium pyrophosphate, 2 mM orthovanadate,
2 mM PMSF, 1% Triton, and complete phosphatase inhibitor cocktail (Roche).
Protein concentration was measured with a BCA Protein Quantification Kit
(Pierce Biotechnology). Protein extracts were run on Criterion gels (Bio-Rad)
and blotted onto nitrocellulose membranes (Millipore). After blocking for 1 hr
at room temperature, immunoblots were incubated overnight at 4C in primary
antibodies against phospho-p70 S6 kinase (Thr389), phospho-STAT3
(Tyr705), STAT3, phospho-S6 ribosomal protein (Ser235/236), phospho-
IRS1 (Ser636/639) (Cell Signaling Technology), p70 S6 kinase (Upstate Bio-
technology), UCP1 (Alpha Diagnostics), Flag (Sigma), or b-actin (Santa CruzMetabolism 8, 459–467, December 3, 2008 ª2008 Elsevier Inc. 465
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Hypothalamic p70 S6 Kinase Drives Energy BalanceBiotechnology, Inc.). Blots were then incubated for 1 hr in fluorescent (Alexa
Fluor 680-conjugated anti-mouse IgG, Invitrogen; or IR Dye 800-conjugated
goat anti-rabbit IgG, Rockland Immunochemicals) or HRP-linked (anti-rabbit
or anti-mouse HRP-linked IgG, Cell Signaling Technology) secondary anti-
bodies, and proteins were detected using either the fluorescence-based Od-
yssey Infrared Imaging System (LI-COR Biosciences) or enhanced chemilumi-
nescence (ECL Plus, Amersham). Quantification was performed with the gel
analyze tool of the Odyssey software (http://www.licor.com/bio/odyssey/
index.jsp) or the NIH ImageJ software (http://rsbweb.nih.gov/ij/), respectively.
Analytical Procedures
Blood glucose levels were determined using a Glucometer (Precision Xtra,
MediSense) and plasma insulin levels using ELISA (Linco Rat Insulin Kit).
Statistical Analysis
All data, presented as means ±SEM, have been analyzed using GraphPad
Prism 5. For all statistical tests, a a risk of 5% was used. All kinetics were
analyzed using a mixed model for repeated measurements. Multiple compar-
isons were tested with an ANOVA and adjusted with Tukey posttest. Single
comparisons were made using one-tail Student’s t tests.
SUPPLEMENTAL DATA
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